CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
ABSTRACT Background COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, severe COVID-19 often occurs in the absence of obvious comorbidities. Guided by the finding of cytomegalovirus (CMV)-specific T cells with some cross-reactivity to SARS-CoV-2 in a COVID-19 intensive care unit (ICU) patient, we decided to investigate whether CMV seropositivity is associated with severe or critical COVID-19.Methods National German COVID-19 bio-sample and data banks were used to retrospectively analyze the CMV serostatus of patients who experienced mild (n=101), moderate (n=130) or severe to critical (n=80) disease by CMV IgG serology. We then investigated the relationship between disease severity and CMV serostatus via statistical models.Results Non-geriatric patients (< 70 years) with severe COVID-19 were found to have a very high prevalence of CMV-seropositivity, while CMV status distribution in individuals with mild disease was similar to the prevalence in the German population; interestingly, this was not detectable in older patients. Prediction models support the hypothesis that the CMV serostatus might be a strong biomarker in identifying younger individuals with a higher risk of developing severe COVID-19.Conclusions We identified ‘CMV-seropositivity’ as a potential novel risk factor for severe COVID-19 in non-geriatric individuals in the studied cohorts. More mechanistic analyses as well as confirmation of similar findings in cohorts representing the currently most relevant SARS-CoV-2 variants should be performed shortly..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 30. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Weber, Simone [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.12.22.21268268 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI033297509 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI033297509 | ||
| 003 | DE-627 | ||
| 005 | 20230429100951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.22.21268268 |2 doi | |
| 035 | |a (DE-627)XBI033297509 | ||
| 035 | |a (biorXiv)10.1101/2021.12.22.21268268 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Weber, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, severe COVID-19 often occurs in the absence of obvious comorbidities. Guided by the finding of cytomegalovirus (CMV)-specific T cells with some cross-reactivity to SARS-CoV-2 in a COVID-19 intensive care unit (ICU) patient, we decided to investigate whether CMV seropositivity is associated with severe or critical COVID-19.Methods National German COVID-19 bio-sample and data banks were used to retrospectively analyze the CMV serostatus of patients who experienced mild (n=101), moderate (n=130) or severe to critical (n=80) disease by CMV IgG serology. We then investigated the relationship between disease severity and CMV serostatus via statistical models.Results Non-geriatric patients (< 70 years) with severe COVID-19 were found to have a very high prevalence of CMV-seropositivity, while CMV status distribution in individuals with mild disease was similar to the prevalence in the German population; interestingly, this was not detectable in older patients. Prediction models support the hypothesis that the CMV serostatus might be a strong biomarker in identifying younger individuals with a higher risk of developing severe COVID-19.Conclusions We identified ‘CMV-seropositivity’ as a potential novel risk factor for severe COVID-19 in non-geriatric individuals in the studied cohorts. More mechanistic analyses as well as confirmation of similar findings in cohorts representing the currently most relevant SARS-CoV-2 variants should be performed shortly. | ||
| 700 | 1 | |a Kehl, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Erber, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Karolin I. |e verfasserin |4 aut | |
| 700 | 1 | |a Jetzlsperger, Ana-Marija |e verfasserin |4 aut | |
| 700 | 1 | |a Burrell, Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Schober, Kilian |e verfasserin |4 aut | |
| 700 | 1 | |a Schommers, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Augustin, Max |e verfasserin |4 aut | |
| 700 | 1 | |a Crowell, Claudia S. |e verfasserin |4 aut | |
| 700 | 1 | |a Gerhard, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Winter, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Spinner, Christoph D. |e verfasserin |4 aut | |
| 700 | 1 | |a Protzer, Ulrike |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Dieter |e verfasserin |4 aut | |
| 700 | 1 | |a D’Ippolito, Elvira |e verfasserin |4 aut | |
| 700 | 1 | |a Busch, Dirk H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.22.21268268 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||
| 953 | |2 045F |a 570 | ||